Our study, which included states across the United States, showed a slight underestimation of the 5-year cancer mortality for non-Hispanic Black women with first estrogen receptor–positive cancers and greater underestimation for non-Hispanic Black and Hispanic women with second estrogen receptor–positive cancers. Here, ESR1 is linked to cancer.